Biocompatibility of extracorporeal circuits in heart surgery.

[1]  L. Gordon,et al.  Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. , 1979, The Journal of clinical investigation.

[2]  M. Dechavanne,et al.  Significant Reduction in the Binding of a Monoclonal Antibody (LYP 18) Directed Against the IIb/IIIa Glycoprotein Complex to Platelets of Patients Having Undergone Extracorporeal Circulation , 1987, Thrombosis and Haemostasis.

[3]  T. Stossel.  Phagocytosis. Pt. 2. , 1974 .

[4]  C. Fisher,et al.  Efficacy of iloprost (ZK36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. , 1987, The Journal of thoracic and cardiovascular surgery.

[5]  Harris Ed,et al.  Collagenases (third of three parts). , 1974 .

[6]  C. Dang,et al.  Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. , 1985, Science.

[7]  D. B. Williams,et al.  The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. , 1984, The Journal of thoracic and cardiovascular surgery.

[8]  G. Weissmann,et al.  Thromboxane generation by human peripheral blood polymorphonuclear leukocytes , 1978, The Journal of experimental medicine.

[9]  E. Lugovskoy,et al.  Quantitation of the inhibitory effect of fibrinogen and its degradation products on fibrin polymerization. , 1982, Thrombosis Research.

[10]  B. Descamps-Latscha,et al.  Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. , 1985, Kidney international.

[11]  E. Fonkalsrud,et al.  Denaturation of plasma proteins as a cause of morbidity and death after intracardiac operations. , 1961, Surgery.

[12]  J. Marx,et al.  The effect of methylprednisolone on complement activation during cardiopulmonary bypass , 1984 .

[13]  S. Hosea,et al.  Role of complement activation in a model of adult respiratory distress syndrome. , 1980, The Journal of clinical investigation.

[14]  T. Stossel,et al.  Evaluation of opsonic and leukocyte function with a spectrophotometric test in patients with infection and with phagocytic disorders. , 1973, Blood.

[15]  J. White,et al.  Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. , 1979, The Journal of clinical investigation.

[16]  M. Hostetter,et al.  Amidation of C3 at the thiolester site: stimulation of chemiluminescence and phagocytosis by a new inflammatory mediator. , 1985, Journal of immunology.

[17]  T. Raffin,et al.  Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. , 1986, The Journal of clinical investigation.

[18]  M. Rola-Pleszczynski,et al.  Leukotrienes augment interleukin 1 production by human monocytes. , 1985, Journal of immunology.

[19]  H. Gewurz,et al.  Complement activation by interaction of polyanions and polycations. , 1975, Immunology.

[20]  R. Allen,et al.  Evidence for the generation of an electronic excitation state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. , 1972, Biochemical and biophysical research communications.

[21]  M. Kazatchkine,et al.  Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. , 1990, Journal of immunology.

[22]  P. Platt,et al.  Neutrophil function and cardiopulmonary bypass in humans. The effects of glucose and non-glucose containing bypass pump priming fluids , 1986 .

[23]  S. Mizel.  Interleukin l and T Cell Activation , 1982 .

[24]  K. Fujikawa,et al.  Surface activation of blood coagulation, fibrinolysis and kinin formation , 1980, Nature.

[25]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[26]  H. Jacob,et al.  Complement-induced granulocyte aggregation in vivo. , 1981, The American journal of pathology.

[27]  W. van Oeveren,et al.  Airborne contamination during cardiopulmonary bypass: the role of cardiotomy suction. , 1986, The Annals of thoracic surgery.

[28]  C. Winterbourn.  Myeloperoxidase as an effective inhibitor of hydroxyl radical production. Implications for the oxidative reactions of neutrophils. , 1986, The Journal of clinical investigation.

[29]  E. Goetzl,et al.  Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. , 1974, The Journal of clinical investigation.

[30]  C. Kluft,et al.  Enhanced fibrinolytic activity during cardiopulmonary bypass in open‐heart surgery in man is caused by extrinsic (tissue‐type) plasminogen activator , 1984, European journal of clinical investigation.

[31]  D. Fearon.  Cellular receptors for fragments of the third component of complement. , 1984, Immunology today.

[32]  H. Isenberg,et al.  The mechanism of action of a single dose of methylprednisolone on acute inflammation in vivo. , 1975, The Journal of clinical investigation.

[33]  J. Fleming.  Production of thiobarbituric acid-reactive material during experimental cardiopulmonary bypass in cows. , 1984, Artificial organs.

[34]  D. Haskard,et al.  Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. , 1986, Journal of immunology.

[35]  E. Corey,et al.  Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Lopes-Virella,et al.  Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. , 1983, Immunology.

[37]  A. Forsgren,et al.  Influence of the Alternate Complement Pathway on Opsonization of Several Bacterial Species , 1974, Infection and immunity.

[38]  M. Turner‐Warwick,et al.  SERUM COMPLEMENT STUDIES DURING AND FOLLOWING CARDIOPULMONARY BYPASS , 1975 .

[39]  W. Blakemore,et al.  Infection by air-borne bacteria with cardiopulmonary bypass. , 1971, Surgery.

[40]  M. Kazatchkine,et al.  Activation of the complement system at the interface between blood and artificial surfaces. , 1988, Biomaterials.

[41]  J. Fehr,et al.  In vivo complement activation by polyanion--polycation complexes: evidence that C5a is generated intravascularly during heparin--protamine interaction. , 1983, Clinical immunology and immunopathology.

[42]  J. Loscalzo,et al.  Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. , 1985, Blood.

[43]  Peirce Ec nd,et al.  Comparative trauma to blood in the disc oxygenator and membrane lung. , 1969 .

[44]  G. Camussi,et al.  Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. , 1981, International archives of allergy and applied immunology.

[45]  S. Ruddy,et al.  Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. , 1979, Journal of immunology.

[46]  R. Lenox,et al.  Exposure of fibrinogen receptors in human platelets by surface proteolysis with elastase. , 1986, Journal of Clinical Investigation.

[47]  D. Chenoweth.  Biocompatibility of hemodialysis membranes: evaluation with C3a anaphylatoxin radioimmunoassays , 1984 .

[48]  L Harvath,et al.  Chemiluminescence of human and canine polymorphonuclear leukocytes in the absence of phagocytosis. , 1978, The Journal of clinical investigation.

[49]  D. Mosher,et al.  Fibronectin mediates attachment of Staphylococcus aureus to human neutrophils. , 1982, Blood.

[50]  P. Barash,et al.  Plasma fibronectin level and clinical status in cardiac surgery patients. , 1983, The Journal of laboratory and clinical medicine.

[51]  M. Sobel,et al.  Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[52]  D. Vergani,et al.  Pathways to complement activation during cardiopulmonary bypass. , 1984 .

[53]  R. van Furth,et al.  Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes. , 1979, Immunology.

[54]  W. Kisiel,et al.  Self-regulation of procoagulant events on the endothelial cell surface , 1985, The Journal of experimental medicine.

[55]  C. Dinarello,et al.  Effects of human interleukin 1 and human tumor necrosis factor on human T lymphocyte colony formation. , 1987, The Journal of clinical investigation.

[56]  R. S. Mitchell,et al.  A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. , 1986, The Journal of thoracic and cardiovascular surgery.

[57]  J. Cavaillon,et al.  In vivo induction of interleukin-1 during hemodialysis. , 1989, Kidney international.

[58]  M. Yoder,et al.  Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. , 1980, The Journal of laboratory and clinical medicine.

[59]  T. Stossel.  Phagocytosis (third of three parts). , 1974, The New England journal of medicine.

[60]  H. Gewurz,et al.  Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. , 1976, Journal of immunology.

[61]  C. Esmon,et al.  Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. , 1986, Blood.

[62]  H. Colten,et al.  Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1 , 1985, The Journal of experimental medicine.

[63]  J. George,et al.  Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. , 1986, The Journal of clinical investigation.

[64]  P. Perlmann,et al.  A rosette assay for the determination of C 1 q receptor‐bearing cells , 1979, European journal of immunology.

[65]  H. Colten,et al.  Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. , 1985, The New England journal of medicine.

[66]  D. Hammerschmidt,et al.  Corticosteroids reversibly inhibit chemotactic peptide-receptor binding and granulocyte response, yet allow desensitization and receptor down- regulation , 1986 .

[67]  E. Salzman,et al.  Elevated Plasma Fibrinopeptide A ana Thromboxane B2 Levels During Cardiopulmonary Bypass , 1980, Circulation.

[68]  J. Demeules,et al.  Ineffectiveness of methylprednisolone in the treatment of pulmonary dysfunction after cardiopulmonary bypass. , 1975, American journal of surgery.

[69]  K. Austen,et al.  A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. , 1985, Journal of immunology.

[70]  A. Fauci,et al.  The effects of interleukin 1 on human B cell activation and proliferation. , 1983, Journal of immunology.

[71]  J. Maher,et al.  Successful intermittent hemodialysis-longest reported maintenance of life in true oliguria (181 days). , 1960, Transactions - American Society for Artificial Internal Organs.

[72]  M. Kazatchkine,et al.  Complement-Mediated Injury , 1986 .

[73]  S. Lewis,et al.  Density changes in leukocytes following hemodialysis or exposure to chemotactic factors. , 1986, American Journal of Nephrology.

[74]  C. Wildevuur.  Towards safer cardiopulmonary bypass , 1981 .

[75]  B. Marshall,et al.  Bradykinin, plasma protein fraction, and hypotension. , 1980, The Annals of thoracic surgery.

[76]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[77]  G. Vercellotti,et al.  Oxygen radical-induced erythrocyte hemolysis by neutrophils. Critical role of iron and lactoferrin. , 1985, The Journal of clinical investigation.

[78]  H. Müller-Eberhard,et al.  C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. , 1979, Journal of immunology.

[79]  L. Eysman,et al.  Reduced platelet activation and improved hemostasis after controlled cardiotomy suction during clinical membrane oxygenator perfusions. , 1985, The Journal of thoracic and cardiovascular surgery.

[80]  W. Hörl,et al.  Plasma levels of granulocyte elastase during hemodialysis: effects of different dialyzer membranes. , 1985, Kidney international.

[81]  E. Kaplan,et al.  Effects of Cardiopulmonary Bypass on the Phagocytic and Bactericidal Capacities of Polymorphonuclear Leukocytes , 1968, Circulation.

[82]  P. V. D. van der Starre,et al.  Inhibition of the hypotensive effect of plasma protein solutions by C1 esterase inhibitor. , 1980, Journal of Thoracic and Cardiovascular Surgery.

[83]  J. Newman,et al.  Lung vascular effects of phorbol myristate acetate in awake sheep. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[84]  R. Colman.  Surface-mediated defense reactions. The plasma contact activation system. , 1984, The Journal of clinical investigation.

[85]  I. Fridovich.  Editorial: Superoxide radical and the bactericidal action of phagocytes. , 1974, The New England journal of medicine.

[86]  R. Bizios,et al.  Pulmonary microvascular effects of arachidonic acid metabolites and their role in lung vascular injury. , 1985, Federation proceedings.

[87]  R. Hornick,et al.  Sources of contamination in open heart surgery. , 1974, JAMA.

[88]  W. van Oeveren,et al.  Prophylactic antibiotic treatment prevents infection after cardiopulmonary bypass: a study in dogs. , 1987, The Annals of thoracic surgery.

[89]  K. Brigham,et al.  Increased Sheep Lung Vascular Permeability Caused by Escherichia coli Endotoxin , 1979, Circulation research.

[90]  A. Dalmasso,et al.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. , 1977, The Journal of clinical investigation.

[91]  J. Roth,et al.  Cell-mediated immunity is depressed following cardiopulmonary bypass. , 1981, The Annals of thoracic surgery.

[92]  The nature and action of granulocyte-macrophage colony stimulating factors. , 1980 .

[93]  P. Clements,et al.  Human lymphocyte subpopulations. Effect of corticosteroids. , 1974, The Journal of clinical investigation.

[94]  L. Wood,et al.  Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen. , 1981, Journal of immunology.

[95]  D. Stroncek,et al.  Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[96]  F. Rosen,et al.  Binding of C3b proceeds by a transesterification reaction at the thiolester site , 1982, Nature.

[97]  D. McGoon,et al.  Bleeding patterns after open-heart surgery. , 1970, The Journal of thoracic and cardiovascular surgery.

[98]  R. Handin,et al.  Enhancement of platelet function by superoxide anion. , 1977, The Journal of clinical investigation.

[99]  H. Hill,et al.  Effect of Chemoattractants on Chemiluminescence , 1978, Infection and immunity.

[100]  J. Zubeldia,et al.  Murine eosinophils and IL-1: alpha IL-1 mRNA detection by in situ hybridization. Production and release of IL-1 from peritoneal eosinophils. , 1990, Journal of immunology.

[101]  L V McIntire,et al.  Mechanical trauma in leukocytes. , 1977, The Journal of laboratory and clinical medicine.

[102]  R. Clancy,et al.  Arachidonate metabolism by human polymorphonuclear leukocytes stimulated by N-formyl-Met-Leu-Phe or complement component C5a is independent of phospholipase activation. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[103]  C. Gerard,et al.  Response of human neutrophils to C5a: a role for the oligosaccharide moiety of human C5ades Arg-74 but not of C5a in biologic activity. , 1981, Journal of immunology.

[104]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[105]  A. Nielsen,et al.  On the kinetics of complement activation, leucopenia and granulocyte-elastase release induced by haemodialysis. , 1985, Scandinavian journal of clinical and laboratory investigation.

[106]  A. Carpentier,et al.  Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. , 1985, The Journal of thoracic and cardiovascular surgery.

[107]  K. Skubitz,et al.  Reversal of hemodialysis granulocytopenia and pulmonary leukostasis: A clinical manifestation of selective down-regulation of granulocyte responses to C5adesarg. , 1981, The Journal of clinical investigation.

[108]  J. Fehr,et al.  Antiadhesive properties of biological surfaces are protective against stimulated granulocytes. , 1985, The Journal of clinical investigation.

[109]  C. Dinarello,et al.  C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. , 1987, Journal of immunology.

[110]  T. Williams,et al.  Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a , 1981, The Journal of experimental medicine.

[111]  P. Unger,et al.  EFFECT OF EXTRACORPOREAL CIRCULATION ON HEMATOPOIESIS AND PHAGOCYTOSIS. , 1963, The Journal of cardiovascular surgery.

[112]  R. Schleimer,et al.  Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. , 1986, Journal of immunology.

[113]  D. Chenoweth,et al.  Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors , 1982, The Journal of experimental medicine.

[114]  C. Kindmark.  Stimulating effect of C-reactive protein on phagocytosis of various species of pathogenic bacteria. , 1971, Clinical and experimental immunology.

[115]  P. Miossec,et al.  Production of interleukin 1 by human endothelial cells. , 1986, Journal of immunology.

[116]  C. Bloor,et al.  Pulmonary injury induced by C3a and C5a anaphylatoxins. , 1980, The American journal of pathology.

[117]  P. Ward,et al.  Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. , 1982, The Journal of clinical investigation.

[118]  L. Chess,et al.  Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 , 1986, The Journal of experimental medicine.

[119]  P. Richardson,et al.  ADP Release from Red Cells Subjected to High Shear Stresses , 1979 .

[120]  D. Birmingham,et al.  Primate erythrocyte-immune complex-clearing mechanism. , 1983, The Journal of clinical investigation.

[121]  L. Henderson,et al.  Hemodialysis Hypotension: The Interleukin Hypothesis , 1983 .

[122]  R. Wiggins,et al.  Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit , 1981, The Journal of experimental medicine.

[123]  R. Wilson,et al.  Hemostasis Changes During Cardiopulmonary Bypass Surgery , 1985, Seminars in thrombosis and hemostasis.

[124]  D. Gemsa,et al.  Lysozyme and Serum Bactericidal Action , 1966, Nature.

[125]  T. Annesley,et al.  Systemic complement activation, lung injury, and products of lipid peroxidation. , 1985, The Journal of clinical investigation.

[126]  R S Kronenberg,et al.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. , 1977, The New England journal of medicine.

[127]  M. Frosch,et al.  Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. , 1976, Journal of immunology.

[128]  S. Krane,et al.  Collagenases (first of three parts). , 1974, The New England journal of medicine.

[129]  W. Opferkuch,et al.  Antibody-independent interaction of the first component of complement with Gram-negative bacteria , 1978, Infection and immunity.

[130]  A. Fauci,et al.  Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. , 1975, The Journal of clinical investigation.

[131]  T. Edgington,et al.  Human Platelets Possess an Inducible and Saturable Receptor Specific for Fibrinogen , 1979, Thrombosis and Haemostasis.

[132]  B. Ghebrehiwet.  The release of lysosomal enzymes from human polymorphonuclear leukocytes by human C3e. , 1984, Clinical immunology and immunopathology.

[133]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. , 1974, Journal of immunology.

[134]  E. Myhre,et al.  Binding of human fibronectin to group A, C, and G streptococci , 1983, Infection and immunity.

[135]  R. Mellins,et al.  Increased Circulating Bradykinin During Hypothermia and Cardiopulmonary Bypass in Children , 1979, Circulation.

[136]  J. White,et al.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. , 1977, The Journal of clinical investigation.

[137]  R. Smith,et al.  Properties of interleukin-1 as a complete secretagogue for human neutrophils. , 1985, Biochemical and biophysical research communications.

[138]  Berger,et al.  Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. , 1984, The Journal of clinical investigation.

[139]  M. Polley,et al.  Human platelet activation by C3a and C3a des-arg , 1983, The Journal of experimental medicine.

[140]  A. Mauer,et al.  LEUKOKINETIC STUDIES. II. A METHOD FOR LABELING GRANULOCYTES IN VITRO WITH RADIOACTIVE DIISOPROPYLFLUOROPHOSPHATE (DFP). , 1960, The Journal of clinical investigation.

[141]  S. Wright,et al.  Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes , 1983, The Journal of experimental medicine.

[142]  J. Fleming,et al.  Increased production of peroxidation products associated with cardiac operations. Evidence for free radical generation. , 1986, The Journal of thoracic and cardiovascular surgery.

[143]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[144]  D. Fearon,et al.  Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. , 1983, Journal of immunology.

[145]  R. Clark,et al.  Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system , 1975, The Journal of experimental medicine.

[146]  M L KARNOVSKY,et al.  The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. , 1959, The Journal of biological chemistry.

[147]  J. Rahal,et al.  Host resistance to Serratia marcescens infection: serum bactericidal activity and phagocytosis by normal blood leukocytes. , 1976, The Journal of laboratory and clinical medicine.

[148]  P. Henson,et al.  Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro. , 1984, The Journal of clinical investigation.

[149]  L. Mcphail,et al.  Exposure of human neutrophils to chemotactic factors potentiates activation of the respiratory burst enzyme. , 1983, Journal of Immunology.

[150]  P. Rigo,et al.  Effects of methylprednisolone on the Fc‐receptor function of human reticuloendothelial system in vivo , 1984, European journal of clinical investigation.

[151]  W. van Oeveren,et al.  Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.

[152]  A. G. Osler,et al.  Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. , 1973, Journal of immunology.

[153]  R. Freeman,et al.  Bacterial culture of perfusion blood after open-heart surgery. , 1980, Thorax.

[154]  A. Budzynski,et al.  Exposure of fibrinogen receptor on human platelets by proteolytic enzymes. , 1981, The Journal of biological chemistry.

[155]  R. Rogers,et al.  Adult respiratory-distress syndrome: changing concepts of lung injury and repair. , 1982, The New England journal of medicine.

[156]  H. Gewurz,et al.  Effects of Hydrocortisone Succinate on the Complement System , 1965, Nature.

[157]  A. Glick,et al.  Degradation of Group A Streptococcal Cell Walls by Egg-White Lysozyme and Human Lysosomal Enzymes , 1972, Infection and immunity.

[158]  H. Colten,et al.  Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG. , 1983, Journal of immunology.

[159]  M. G. Lötter,et al.  Kinetics and sites of sequestration of indium 111-labeled human platelets during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[160]  D. E. Rogers,et al.  THE SURVIVAL OF STAPHYLOCOCCI WITHIN HUMAN LEUKOCYTES , 1952, The Journal of experimental medicine.

[161]  W. van Oeveren,et al.  Bubble oxygenation and cardiotomy suction impair the host defense during cardiopulmonary bypass: a study in dogs. , 1987, The Annals of thoracic surgery.

[162]  J. Weiler,et al.  Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin , 1978, The Journal of experimental medicine.

[163]  D. Chenoweth.  Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. , 1984, Artificial organs.

[164]  J. Salmon,et al.  Release of leukotriene B4 from human neutrophils and its relationship to degranulation induced by N-formyl-methionyl-leucyl-phenylalanine, serum-treated zymosan and the ionophore A23187. , 1983, Immunology.

[165]  L. Aledort,et al.  Functional changes in platelets during extracorporeal circulation. , 1975, The Annals of thoracic surgery.

[166]  M. Hamberg,et al.  On the formation and effects of thromboxane A2 in human platelets. , 1976, Acta physiologica Scandinavica.

[167]  A. Tärnvik,et al.  Influence of complement on the chemiluminescent response of human leukocytes to immune complex , 1980, Infection and immunity.

[168]  J. Soons,et al.  Controlled Cardiotomy Suction during Clinical Bubble Oxygenator Perfusions , 1985, The Thoracic and cardiovascular surgeon.

[169]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[170]  A. Agostoni,et al.  PMN C5a-receptor down regulation is not involved in recovery from C5a-induced neutropenia. , 1987, ASAIO transactions.

[171]  E. Goetzl,et al.  Heterogeneity of Human Polymorphonuclear Leukocyte Receptors for Leukotriene B4 Identification of a Subset of High Affinity Receptors That Transduce the Chemotactic Response , 1980 .

[172]  J. Volanakis,et al.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.

[173]  P. Peterson,et al.  Influence of serum concentration on opsonization by the classical and alternative complement pathways , 1980, Infection and immunity.

[174]  D. Hinshaw,et al.  Glutathione cycle activity and pyridine nucleotide levels in oxidant-induced injury of cells. , 1985, The Journal of clinical investigation.

[175]  H. Gewurz,et al.  Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. , 1975, Journal of immunology.

[176]  Karp Rb,et al.  Changes in serum complement and immunoglobulins following cardiopulmonary bypass. , 1972 .

[177]  N. Cooper.  The classical complement pathway: activation and regulation of the first complement component. , 1985, Advances in immunology.

[178]  G. D. Ross.  Analysis of the different types of leukocyte membrane complement receptors and their interaction with the complement system. , 1980, Journal of immunological methods.

[179]  G. Camussi,et al.  Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. , 1981, Immunology.

[180]  F. Fekety,et al.  Transient defects in phagocytic functions during cardiopulmonary bypass. , 1974, The Journal of thoracic and cardiovascular surgery.

[181]  A. Schechter,et al.  Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. , 1980, Biochemistry.

[182]  R. S. Kent,et al.  Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells. , 1985, The Journal of clinical investigation.

[183]  J. Cavaillon,et al.  C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. , 1987, Journal of immunology.

[184]  R. Golub,et al.  Chemiluminescence in microamounts of whole blood for investigation of the human phagocyte oxidative metabolism function. , 1982, Annales d'immunologie.

[185]  J. O’Shea,et al.  Fibronectin-enhanced phagocytosis of an alternative pathway activator by human culture-derived macrophages is mediated by the C4b/C3b complement receptor (CR1). , 1985, Journal of Immunology.

[186]  C. Wildevuur,et al.  Clinical study of blood trauma during perfusion with membrane and bubble oxygenators. , 1982, The Journal of thoracic and cardiovascular surgery.

[187]  M. Kazatchkine,et al.  Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b , 1979, The Journal of experimental medicine.

[188]  N. Gleicher,et al.  THE RED-CELL IMMUNE SYSTEM , 1981, The Lancet.

[189]  Harris Ed,et al.  Collagenases (second of three parts). , 1974 .

[190]  T. Kooistra,et al.  Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells , 1986, The Journal of experimental medicine.

[191]  R. Stroud,et al.  Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. , 1976, Immunochemistry.

[192]  M. Kazatchkine,et al.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. , 1981, The Journal of clinical investigation.

[193]  R. Rosenberg,et al.  The purification and mechanism of action of human antithrombin-heparin cofactor. , 1973, The Journal of biological chemistry.

[194]  R. Spragg,et al.  Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. , 1983, The Journal of clinical investigation.

[195]  P. Lachmann,et al.  Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. , 1985, Journal of immunology.

[196]  G. J. Jones,et al.  The effect of surgery with cardiopulmonary bypass on alveolar-capillary barrier function in human beings. , 1985, The Annals of thoracic surgery.

[197]  R. Discipio.  The activation of the alternative pathway C3 convertase by human plasma kallikrein. , 1982, Immunology.

[198]  P. Ward.  A PLASMIN-SPLIT FRAGMENT OF C'3 AS A NEW CHEMOTACTIC FACTOR , 1967, The Journal of experimental medicine.

[199]  L. Boxer,et al.  Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. , 1981, Blood.

[200]  H. Müller-Eberhard,et al.  Anaphylatoxins: C3a and C5a. , 1978, Advances in immunology.

[201]  E. Goetzl,et al.  Enhancement of human neutrophil adherence by synthetic leukotriene constituents of the slow-reacting substance of anaphylaxis. , 1983, Immunology.

[202]  D. Roberts,et al.  Evaluation of red cell damage during cardiopulmonary bypass. , 1985, Scandinavian journal of thoracic and cardiovascular surgery.

[203]  H. Perez,et al.  Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells. , 1986, Journal of immunology.

[204]  J. Griffin,et al.  The biochemistry and pathophysiology of the contact system of plasma. , 1982, Advances in immunology.

[205]  M. Kazatchkine,et al.  The Human Alternative Complement Pathway : Biology and Immunopathology of Activation and Regulation1 , 1982 .

[206]  P. Henson,et al.  Intracellular control of human neutrophil secretion. I. C5a-induced stimulus-specific desensitization and the effects of cytochalasin B. , 1978, Journal of immunology.

[207]  R. Johnston,et al.  Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b. , 1979, Journal of immunology.

[208]  E. Blackstone,et al.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. , 1981, The New England journal of medicine.

[209]  M. Kazatchkine,et al.  Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. , 1979, Journal of immunology.

[210]  M. Kazatchkine,et al.  The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. , 1988, Molecular immunology.

[211]  G. Camussi,et al.  The release of platelet-activating factor from human endothelial cells in culture. , 1983, Journal of immunology.

[212]  M. Katori.  Inhibition of Kinin Formation by a Kallikrein Inhibitor during Extracorporeal Circulation in Open‐heart Surgery , 1975, Circulation.

[213]  S. Vernick,et al.  Effect of blood microfilters on complement activity in human plasma. , 1983, Biomaterials, medical devices, and artificial organs.

[214]  H. T. ten Duis,et al.  Hematologic aspects of cardiotomy suction in cardiac operations. , 1980, The Journal of thoracic and cardiovascular surgery.

[215]  H. Kehlet,et al.  Complement activation during surgical procedures. , 1978, Surgery, gynecology & obstetrics.

[216]  B. Babior,et al.  Oxygen-dependent microbial killing by phagocytes (second of two parts). , 1978, The New England journal of medicine.

[217]  E. Blackstone,et al.  Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.

[218]  Patrícia,et al.  Effect of corticosteroids on the human monocyte IgG and complement receptors. , 1975, The Journal of clinical investigation.

[219]  J. Weiler,et al.  Methylprednisolone inhibits the alternative and amplification pathways of complement , 1982, Infection and immunity.

[220]  M. Kazatchkine,et al.  Relative inefficiency of terminal complement activation. , 1988, Journal of immunology.

[221]  W. Seeger,et al.  Increased pulmonary vascular resistance and permeability due to arachidonate metabolism in isolated rabbit lungs. , 1982, Prostaglandins.

[222]  F. Li,et al.  Platelet adhesion to artificial surfaces: consequences of flow, exposure time, blood condition, and surface nature. , 1971 .

[223]  T. Stossel,et al.  Phagocytosis (first of three parts). , 1974 .

[224]  D. Kasper,et al.  The role of complement and antibody in opsonophagocytosis of type II group B streptococci. , 1986, The Journal of infectious diseases.

[225]  M. Polley,et al.  Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex , 1979, The Journal of experimental medicine.

[226]  A. Churg,et al.  Production of acute pulmonary injury by leukocytes and activated complement. , 1980, Surgery.

[227]  M. A. Bray,et al.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes , 1980, Nature.

[228]  J. August,et al.  Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro. , 1981, The Journal of clinical investigation.